by Allen & Overy
When a national ‘champion’ is at stake, lively political and media debate often follows, sometimes even where the sector involved is not particularly ‘sensitive’. This is unsurprising in markets facing slow economic growth and, more recently, there has been an interesting interplay between expanding sanctions regimes and policy in this area. […] Read more
By Paul Bjacek – Accenture Contributor: Kurt Eichhorn Mergers and acquisitions in the global chemicals industry have tumbled from their highs of the 2007-2009
by A.T. Kearney
Since China first opened to the world with the 1978 economic reforms, the country’s GDP has made unprecedented progress. It is a remarkable growth story. Although there is a big gap to close to catch up with the United States, China ranked second in the world in real GDP by 2013. By 2014, 100 Chinese companies were in the Fortune 500, up from 11 in 2000 and with petrochemical firm Sinopec holding the number-three spot. […] Read more
By Jian Sun, Sherri He, Joachim von Hoyningen-Huene, Andreas Graef, Thomas Luedi, Frankie Leung, Jürgen Rothenbuecher, Bastian Sauerberg – A.T. Kearney Since China first opened to the world with the
Available in our e-library on M&A at IMAA! Authors: Paul Pignataro Publisher: John Wiley Year: 2015 (March) ISBN: 978-1-118-90871-6 Content Paul Pignataro reveals
by Baker & McKenzie
When you look at the numbers, there’s no question why global pharmaceutical companies have set their sights on emerging markets for future growth. From 2012 to 2017, global pharmaceutical sales are expected to rise 13% in the “pharmerging markets,” compared to 2% for the top mature markets, according to the IMS Institute for Healthcare Informatics. […] Read more
Pharmerging markets report By Baker & McKenzie Introduction When you look at the numbers, there’s no question why global pharmaceutical companies
Trainings
In order to become a charterholder you need to complete one of the IMAA programs
